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Adult age-specific colorectal cancer incidence rates increase exponentially from maturity,
reach a maximum, then decline in extreme old age. Armitage and Doll (1) postulated that
the exponential increase resulted from “n” mutations occurring throughout adult life in
normal “cells at risk” that initiated the growth of a preneoplastic colony in which subse-
quent “m” mutations promoted one of the preneoplastic “cells at risk” to form a lethal
neoplasia. We have reported cytologic evidence that these “cells at risk” are fetal/juvenile
organogenic, then preneoplastic metakaryotic stem cells. Metakaryotic cells display stem-
like behaviors of both symmetric and asymmetric nuclear divisions and peculiarities such
as bell shaped nuclei and amitotic nuclear fission that distinguish them from embryonic,
eukaryotic stem cells. Analyses of mutant colony sizes and numbers in adult lung epithelia
supported the inferences that the metakaryotic organogenic stem cells are constitutively
mutator/hypermutable and that their contributions to cancer initiation are limited to the
fetal/juvenile period. We have amended the two-stage model of Armitage and Doll and
incorporated these several inferences in a computer program CancerFit v.5.0. We com-
pared the expectations of the amended model to adult (15–104 years) age-specific colon
cancer rates for European-American males born 1890–99 and observed remarkable concor-
dance. When estimates of normal colonic fetal/juvenile APC and OAT gene mutation rates
(∼2–5×10−5 per stem cell doubling) and preneoplastic colonic gene loss rates (∼8×10−3)
were applied, the model was in accordance only for the values of n 2 and m 4 or 5.= =
Keywords: stem cells, metakaryotic, mutator, hypermutable, cancer model
INTRODUCTION
The age-specific incidence of colorectal cancer is here reconsid-
ered in terms of stem cell growth and oncomutation in normal
stem cells of the fetal/juvenile period (tumor initiation) and there-
after in the preneoplastic stem cells of colonic adenomas (tumor
promotion) from which lethal colonic adenocarcinomas arise.
This reconsideration was prompted by discoveries concerning
metakaryotic stem cells in organogenesis and carcinogenesis (2–5)
and by evidence that normal organogenic stem cells experience
Abbreviations: APC, adenomatous polyposis coli gene; FAPC, familial adenoma-
tous polyposis coli; OAT, sialylmucin acid O-acetyl transferase gene; t, age interval
of death; h, cohort (birth years, gender, ethnic group); y, calendar year of death;
MOR(h,t ), number of deaths; POP(h,t ), number in population; OBS (h,t ), raw
death rate, MOR(h,t )/POP(h,t ); OBS∗(h,t ), raw death rate corrected for coincident
deaths, corrected death rate; INC (h,t ), corrected death rate adjusted for survival
of disease to approximate incidence; CAL(h,t ), values of incidence predicted by
amended model; GOF(h,t ), goodness of fit of CAL(h,t ) to INC(h,t ).
unexpectedly high rates of genetic changes required for tumor
initiation (6).
OVERVIEW OF ORGANOGENESIS AND CARCINOGENESIS
The human body arises from a single fertilized egg and in a series
of cell divisions creates a body mass of some 244 cells at maturity.
However, these cells are not homogeneous but are apportioned
among the organs each containing several distinct tissue layers
containing in turn one or more histologically recognizable cell
types. The epithelial layers of many solid organs, such as those of
the gastrointestinal tract, the lung, breast and prostate are of special
interest because it appears that the vast majority of lethal tumors
arise from these layers. Each of these epitheloid or adenocarci-
nomatous (gland-like) tumors displays histological organization
that, however distorted, resembles the histological organization
of that organ during fetal growth and development (7). In the
case of the human colon, histologic alterations at multiple foci in
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the embryonic mid- and hind gut begin at about the 5th week
of gestation; by the 25th week one may observe the parallel array
of crypts that open to the colonic lumen numbering about one
million (∼220) in a newborn and about ten million (∼223.25) at
maturity with each crypt containing about two thousand (∼211)
epithelial cells.
In adult epithelial tissues slowly growing epitheloid colonies
(adenomas) are observed from which more rapidly growing
colonies emerge (adenocarcinomas). From some, but not all, ade-
nocarcinomas even more rapidly growing metastases emerge that
are distributed throughout the body. It appears that each succeed-
ing step represents an event in a single stem cell such that each
form of lesion is clonal.
METAKARYOTIC STEM CELLS OF ORGANOGENESIS AND
CARCINOGENESIS
Embryonic stem cell lines derived from human blastulas are
eukaryotic cells. They have spheroidal nuclei enclosed in a nuclear
membrane that exists as an organelle within the cell cytoplasm.
Their DNA content doubles in an S-phase that is completed a
few hours before the condensation of chromosomes in prophase
marks the beginning of mitosis by which the two sister genomes
are segregated during cell fission to form two sister cells.
But beginning in the fourth- to fifth-week of gestation and in
all preneoplasias and neoplasias examined a different kind of cell
is found in which the genomic DNA is contained in a large, hollow,
bell shaped structure. These appear to arise from precursor cells
with spherical nuclei, i.e., resembling eukaryotic embryonic stem
cells, in which a belt of condensed chromatin marks the beginning
of an amitotic process in which two separate facing hemispheres
are created each containing the diploid amount of DNA. Soon
these bell shaped nuclei are enclosed in a sarcomeric pod or tubular
syncytium (3, 4). In the∼5th–12th week of gestation the number
of bell shaped nuclei per tubular syncytium increases by a form
of symmetric amitosis resembling one paper cup separating from
another. The number of syncytia increases rapidly and distribute
non-randomly in space and time within fetal meta-organs up to
about the 12th week. Then the syncytia disappear but the bell
shaped nuclei persist as mononuclear cells with oblate spheroidal
mucinous cytoplasms. These continue to increase by symmetric
cup-from-cup amitoses without any detectable condensation of
chromosomes. Bell shaped nuclei are appended to, rather than
enclosed in, the cytoplasmic organelles. DNA doubles not in an
S-phase preceding nuclear fission as in eukaryotes but during
and after amitotic segregation of bell shaped sister nuclei (2–4).
The genomes of bell shaped nuclei between doublings appear to
be organized in a set of circular structures each containing one
or more homologously paired chromosomal elements specifically
end-joined at their telomeres (5).
Both in the syncytial and post syncytial period of development
bell shaped nuclei of the developing colon undergo asymmet-
ric amitoses in which any of at least nine distinct morphologic
forms of closed nuclei emerge from bell shaped nuclei. These sub-
sequently undergo a series of DNA doublings and mitoses that
create the eukaryotic cells that populate the crypts of the colonic
epithelium throughout the second and third fetal trimesters and
the juvenile period. Cells with bell shaped nuclei external to
cytoplasmic organelles are located at the bases of colonic crypts
both in the developing fetus and colonic adenocarcinomas. After
maturity cells with bell shaped nuclei are rarely found at the base
of colonic crypts or epithelia of any organs observed to date but
are invariably found in incipient micro-colonies in colonic ade-
nomas and at the base of crypts in colonic adenocarcinomas and
their derived metastases (3).
Insofar as these cells displayed cytologic behaviors distinguish-
ing them from eukaryotic cells, they were designated as metakary-
otic cells because they were first observed in the formation of
meta-organs during the 5th- to 12th-week of gestation (3). Their
discovery in the development of many organs including those of
the developing digestive and nervous systems and derived tumors
as well as their appearance in a developing plant marked them as
an important and general part of organogenesis and carcinogen-
esis with evolutionary origins preceding the separation of plants
and animals (4).
The demonstration that the bell shaped nuclei of metakaryotic
cells underwent both symmetric amitoses to increase in number
and asymmetric amitoses to form the mitotic parenchymal cells of
the organ or tumor marked them as organogenic or carcinogenic
stem cells (2–4). These observations confirmed and extended the
observations and interpretations of Child (1907) that the gonadal
development of a sheep tapeworm involved a series of amitotic
divisions followed by a mitotic expansion and directly contra-
dicted the opinion of Boveri (8) that tissue development and
tumor growth depended solely on mitotic fission.
HIGH RATES OF STEM CELL MUTATION IN A DEVELOPING HUMAN
ORGANS
Measurement of five specific nuclear point mutations and 17
specific mitochondrial point mutations in the DNA of micro-
anatomical samples of adult human lung epithelia revealed unex-
pectedly high numbers of somatic mutations in the TP53, KRAS,
and HPRT1 nuclear genes and in the mitochondrial genome
(bp10,100–10,101) (6, 9). Plotting mutant colony numbers as
a function of colony size for the lung data revealed a Luria–
Delbruck distribution (10). This finding indicated that the muta-
tions occurred at a constant rate per organogenic stem cell
doubling during the exponential growth of the organ, i.e., the
fetal/juvenile period. Furthermore, mutant fractions in the lung
epithelium did not increase with age indicating that mutation rates
in maintenance stem cells of lung turnover units were much lower
than in organogenic stem cells. Consistent with this interpreta-
tion was the observation that overall lung mutant colony numbers
of any size did not significantly increase with age in adults. Using
these data we estimated a gene-inactivation mutation rate per lung
stem cell doubling of about 2–4× 10−4 for the TP53 and HPRT1
genes.
Histological enumeration of colonic polyps carrying a somatic
mutation of the APC gene in FAP patients’ colons (11) and of
colonic crypts carrying a somatic mutation in the sialomucin
acid O-acetyl transferase (OAT) gene (12) provided data that
have allowed us to estimate that gene-inactivation mutation rates
for stem cells of the developing colon are about 2–5× 10−5. As
the gene-inactivation rate of human B-cells grown in culture has
been estimated as ∼2× 10−7 per cell doubling (13) it is clear
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that fetal/juvenile stem cell mutation rates are some 100 (colon)
to 1000× (lung) higher than previously associated with human
eukaryotic cells. Levels of loss of heterozygosity for polymorphic
markers in colonic preneoplasia of ∼0.25 allow estimation of pre-
neoplastic gene deletion rates of about 8× 10−3 per gene copy
per preneoplastic stem cell doubling (14). Based on these obser-
vations we inferred that high rates of genetic change or “genomic
instability,” generally associated with preneoplastic and neoplas-
tic growths, are a characteristic of the metakaryotic stem cells of
human organogenesis.
MATERIALS AND METHODS
BIOLOGICALLY BASED ALGEBRAIC CANCER MODELS
We have incorporated these new biological findings/inferences in a
revised model of carcinogenesis adopting and extending the two-
stage model first proposed and expressed in algebraic form by
Armitage and Doll (1): “n” initiating mutations in an organogenic
metakaryotic stem cell permit it to (a) avoid metamorphosis to a
non-growing maintenance stem cell at maturity and (b) continue
to grow at approximately the juvenile growth rate as a preneoplas-
tic colony; “m” promoting events in a preneoplastic metakaryotic
stem cell permit it to form a rapidly growing lethal neoplastic
colony.
The model so revised permits, for the first time, the use of
key parameters derived from clinical observations: the number of
stem cell doublings during organogenesis (amax) and the rates per
metakaryotic organogenic stem cell doubling of n events neces-
sary for initiation (Ri, Rj, . . ., Rn) and the rates per preneoplastic
metakaryotic stem cell doubling of m events necessary for pro-
motion (RA, RB, . . ., Rm). Comparison of quantitative predictions
based on the revised model to the age-specific incidence rate for
that cancer in a population in which data are available for the
entire adult life span of ∼15–104 years tests the general accuracy
of the assumptions incorporated in the model.
One-stage models
Cohnheim inferred from similarity of histologic organization
between second trimester fetuses and adenocarcinomas that
tumors originated in cells responsible for embryonic/fetal growth
and differentiation (7). Boveri inferred from the presence of altered
chromosome numbers and structures in some primary tumors and
metastases that tumors involved chromosomal/genetic changes
(8). In the early 1950s several theorists sought to reconcile the
increasing rate of cancers with adult age in terms of new under-
standings of genetics and genetic change particularly the demon-
stration that human tumors were of clonal origin. They posited
that any single cell at risk in a static, adult cell population could be
created from normal “cells at risk” by “n” required genetic events
(15–17). In particular, Armitage and Doll (17) examined human
age-specific mortality rates, OBS(h,t ) for several cancer sites and
noted a relationship, limited to the age range of 25–75, of the form
log OBS(h,t )= log K t (n − 1)= log K + (n− 1)log t, where“n”was
the number of required oncogenic events in a constant number of
cells at risk.
This treatment, presented as a hypothesis by the authors,
suggested that n might be 5, 6, or 7, the source of the idea
that such numbers of oncomutations are required in human
carcinogenesis (17).
Two-stage models
However, the“one-stage”models did not account either for growth
of stem cell numbers in development or for clinically observed
slowly growing preneoplastic lesions such as colonic adenomas.
Platt was apparently the first to ask if early mutations could create
a cell population with a growth advantage in which later necessary
oncomutations could occur (18). Armitage and Doll responded to
Platt’s suggestion by testing a model in which a single normal “cell
at risk” was initiated by “n” required events could give rise to an
exponentially growing preneoplastic colony in which any “cell at
risk” was promoted to a tumor forming cell by “m” independent
events (1). They chose the words initiation and promotion from
the findings in experimental animal studies that certain chemical
treatments could create a latent capability of tumor formation (ini-
tiation) that subsequent chemical treatments could provoke into
growth of a visible neoplasia (promotion) (19). Their reasoning
may be represented as log OBS(t )= log Le−µt= log L+µt where
L is a constant related to the product of initiation and promotion
mutation rates and µ is the annual growth rate of preneoplas-
tic cells at risk in adult tissue. Initiation events were posited to
occur at constant annual rates per person from birth through old
age. Human populations were considered to be homogeneous with
regard to risk. It was noted that initiated cells at risk “had sufficient
selective advantage to double in number about every 5 years” (1).
They noted that both the“one-stage”and“two-stage”models could
be fit by judicious choice of parameter values to age-specific mor-
tality data for the age of death interval 25–75 years and, therefore,
they could not exclude either possibility on this basis alone.
Limitation of “two-stage” model: declining cancer rates in extreme
old age
However, neither the one-stage nor two-stage cancer models
accounted for age-specific rates outside of the interval of 25–
75 years. The rates of most forms of cancer decline from the
first years of life to a minimum in mid-juvenile years, increase
sub-exponentially into old age, reach a maximum then decline
in extreme old age (Figure 1) (14, 20). Doll’s group ascribed
the apparent maximum raw mortality rate in old age to either
under-diagnosis of cancer in old age or the presence of a sub-
population that was not at risk (21). We algebraically amended
the basic two-stage model using the suggestion of to account for
a subfraction of the population, F, could be at risk for all of the
events required for carcinogenesis in a particular organ, while the
subfraction (1− F) was not at risk. This modification resulted in
improved fits of prediction to observed incidence rates for col-
orectal cancer in the United States in old and extreme old age (14,
20). Predictions even more closely related to cancer incidence data
may be expected if explicit partitioning of the general populations
into subpopulations differing in quantitative risk factors are intro-
duced, e.g., oncomutation rates (6), preneoplastic growth rates,
and even individual size at maturity. Other biological hypothe-
ses exist. For instance, it has been suggested that senescence itself
suppresses preneoplastic or neoplastic growth (22, 23).
Initiation
Kinds and number of initiation mutations, n. More than
50 years after Armitage and Doll’s pioneering postulates, the
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FIGURE 1 | Lower gastrointestinal cancer in European-American males,
calendar years of death, 1890–2006. (A) Transformations linking raw
mortality rates, OBS(h,t ), with estimates of incidence rates, INC(h,t ). Shown
are the raw mortality rate function, OBS(h,t ), for h=1890–99 corrected for
coincident forms of death which becomes the function OBS*(h,t ) which, in
turn, corrected for historically increasing survival rate, becomes the
incidence rate function, INC(h,t ). Also shown is INC(h=1900–09, t ).
(B) OBS*(h,t ), coincidence corrected death rates for birth cohort intervals,
h=1800–09, . . ., 2000–06, vs. age intervals of death, “t”=0.5, 1, 2, 3, 4,
5–9, . . ., 100–104. (C) OBS*(h,y ), coincidence corrected death rates for
birth-decade intervals, h vs. calendar year of death intervals,
“y”=1900–1904, . . ., 2000–2004, 2005–2006. (D) OBS*(t,y ), coincidence
corrected death rates for intervals of age at death “t” vs. calendar year of
death intervals, “y.”
number, nature, and origins of oncomutations that initiate the
slow growth of preneoplastic lesions and later promote a preneo-
plastic cell to the rapid growth of neoplastic lesions remain obscure
for most common cancers, e.g., lung, breast, prostate, pancreas.
For a few common cancer types, initiation events have been con-
vincingly associated with the loss of both maternal and paternal
alleles of specific autosomal tumor suppressor genes, e.g., colorec-
tal (APC), kidney (VHL), nervous system (NF1, NF2), and basal
skin (PTCH ) cancers (24). Accordingly, we chose colorectal or
“lower GI tract” cancer as a first example. The inherited early
onset syndrome of multiple adenomatous polyps in the lower GI
tract (colon and rectum), familial adenomatous polyposis coli or
FAP, usually arises from inherited heterozygosity of the APC gene.
Loss of the second APC allele represents a necessary and pos-
sibly sufficient event for initiation followed by appearance of a
growing adenomatous polyp as a preneoplastic lesion, i.e., the
number of required colonic initiating mutations is equal to, or
greater than, 2.
The deductions of Knudson (25) based on observation and
analysis of certain inherited pediatric cancer syndromes such as
Wilm’s tumor and retinoblastoma had previously indicated that
two mutations in an organogenic lineage were necessary and suf-
ficient to cause these diseases. A two-stage cancer model explicitly
positing n= 2 was subsequently developed (26). Others moti-
vated or dismayed by the large number and kinds of genetic and
epigenetic changes displayed by most, but not all, cancers have
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postulated that a much greater number of successive events are
required (27, 28).
Limitation to the period of organ development. Influenced by
studies and models of mutation in bacterial populations (10) two
cancer modelers independently noted that the age-specific expo-
nential increase in cancer rates in adults might have origins in
the approximately exponential increase in organ cell number and,
thus, initiated cell number from the beginning of organogenesis
to maturity (29–31). A two-stage model of colon cancer incorpo-
rating mutation in juvenile (but not fetal) growth periods yielded
expectations in concordance with observation (14, 20). A gen-
eral, untested assumption that fetal mutation rates would/should
be very low seems to have blocked further examination of the
possibility that fetal mutation was a strong driver of tumor initi-
ation. This idea was dispelled by direct assay at the DNA level of
point mutations in micro-anatomical samples of upper bronchial
epithelium from 15 healthy human lungs (6, 32).
In this present effort addressing mutations and cancers of the
colon we have had recourse to literature reports from which it is
possible to obtain reasonable first estimates of fetal/juvenile muta-
tion rates in development of that organ. For instance, patients
heterozygous for the APC gene are reported to have thousands
of adenomatous polyps in adulthood presumably resulting from
a single mutation inactivating the single active inherited APC
allele. The inherited condition appears to be fully penetrant: all
known APC heterozygotes have displayed multiple adenomas and,
if untreated, adenocarcinomas. It should also be noted that the
number of adenomatous polyps varies widely within family mem-
bers afflicted with FAP, an observation extended to mutation rates
in human lung epithelium that were found to vary about sevenfold
from upper to lower decile estimates (6, 11, 24, 32).
Here we regard polyp number as a probable underestimate
of actual mutated stem cells as many patients die before polyps
arising late in juvenile development could be recognized. Allow-
ing for 5000–10,000 potential polyps from the stem cells forming
about 107 colonic crypts suggests that events per stem cell dou-
bling (∼23.25 to create the crypt number observed) would be
of the order of 2–4× 10−5 gene-inactivating events per stem cell
doubling for the APC gene. These events would include point
mutations, chromosomal, and other possibilities including reci-
procal recombinations. Our derived estimate of the geometrical
mean rate of loss of the second allele of OAT in colons of het-
erozygotes is also∼2–4× 10−5 (12). We later use these estimates to
compare initiation mutation rates predicted for different possible
numbers, “n” of required initiation mutations.
Nature of cells in which initiation mutations occur. Confusion
arises in the use of these models in that the earliest efforts treated
the number of “cells at risk” of initiation or promotion as con-
stant (15–17) while the 1957 effort of Armitage and Doll treated
initiation as occurring in a constant number of cells at risk while
promotional mutations occurred in a growing population of ini-
tiated cells (1). Normal “cells at risk” might have included only
stem cells or any of the stem plus non-stem cells of an epithelial
maintenance turnover unit (14, 20). Here we explore the possi-
bility that normal “cells at risk” are solely metakaryotic stem cells
(3, 4) that may be readily detected and counted in growing tissues,
preneoplastic, and neoplastic lesions. Of course, there are other
possibilities, the study of human organogenic and carcinogenic
stem cells is still in its own gestation period.
Promotion
Clinical observations have shown that preneoplastic lesions of
several organs continue to grow after maturity and give rise to
lethal neoplasias through extreme old age. Promotional genetic
changes or other events, if any, may therefore be hypothesized
to occur throughout adult life in preneoplastic colonies in either
symmetric (net growth) or asymmetric (turnover) amitoses of ini-
tiated metakaryotic stem cells. Uncertainties abound regarding the
process called “promotion.”
First, it must be emphasized that no genetic or epigenetic events
have yet been found that fulfill the logical requirements for a rare
human promotion event. Secondly, as pointed out by Peto, math-
ematical analyses of non-linear age-specific incidence functions
alone cannot define the number of “n” initiation or “m” promo-
tion mutations using Armitage and Doll’s one-stage or two-stage
models (33).
Progression
The steps toward deaths from primary neoplasias such as colonic
adenocarcinomas and/or their metastases may involve one or more
additional mutations/events in a stem cell during primary tumor
growth. Here we accept the approximation of ∼2.5 years between
the last required promotion event and death (1).
USING MORTALITY AND SURVIVAL DATA TO ESTIMATE AGE-SPECIFIC
INCIDENCE, INC(h,t )
U.S. age-specific cancer mortality rates (1900–2006)
Trial of any model of age-specific cancer experience requires a
robust set of data to which predictions may be compared. The
MIT-administered website1 provides researchers with age-, gen-
der, ethnicity-, and birth cohort-specific population and mortality
data organized as Excel® files with several different forms of tabular
and graphic summaries. Data are provided as recorded annually
from 1900 through 2006 in the USA for most common cancer
types and other major forms of mortality such as cardiovascu-
lar and cerebrovascular diseases. (Data for Japan are provided for
most forms of cancer from 1952 through 1996.) These data per-
mit examination of disease-specific mortality rates for the entire
United States throughout the adult lifetimes (15–104 years) of per-
sons of the same birth year or decade cohort born from∼1885 to
1910. Earlier birth decades lack data that were unrecorded before
1900. Later birth decade cohorts have not yet reached extreme
old age.
Many forms of cancer such colorectal, pancreatic, and brain
cancers as well as vascular diseases and Type II diabetes display
a sub-exponential increase in mortality rates from maturity to a
maximum then declining rate in extreme old age. The calculated
model presented here, CAL(h,t ) is aimed at these forms of disease.
(However, cancers of other organs including pharynx, tongue,
1http://mortalityanalysis.mit.edu

























































Kini et al. Metakaryotic stem cell cancer model
testes, ovaries, uterus, and breast display a clearly different age-
specific mortality rate function in which a distinctly more rapid
rise in age-specific mortality rates are observed in young than in
middle to older aged adults.) Data for many cancer sites are further
limited because U.S. national recording began later than 1900, e.g.,
lung or pancreas in 1930.
This database is updated using ASCII files from the National
Center for Health Statistics. U.S. data is organized by gender and
major ethnic groups: European Americans and Non-European
Americans, the latter comprising primarily African Americans.
Information for years 1900–1991 were manually transcribed and
re-organized from successive volumes of Vital Statistics of the
United States published by the U.S. Census Bureau (1900–1935)
and then by the U.S. Public Health Service (1936–1992) (Pablo
Herrero-Jimenez), from digital versions of the same publication
(1992–1997) (Efren Gutierrez) and directly from comprehensive
ASCI files since 1998 (Karl Rexer, Rebecca Kusko, Lohith G. Kini).
The computer program Cancer Fit v.5.0 described below interfaces
with downloaded Excel® files from this data set.
As originally organized by the U.S. Census Bureau, the number
of deaths for each form of mortality were recorded in each cal-
endar year, y, for cohorts defined by gender, ethnicity, and age
of death intervals, t = 0, 1, 2, 3, 4, 5–9, . . ., 100–104 years. In
1900 the two major ethnic designations were “white” and “non-
white.” As “white” included families immigrating from Europe
or through former Spanish, French, and Portuguese colonies of
North and South America the classification “white” was denom-
inated as European-American [EAM (male), EAF (female)] and
the“non-white” consisting primarily of families of African descent
was designated Non-European-American [NEAM (male), NEAF
(female)].
Transforming raw mortality data to incidence estimates
Any single recorded death included the (a) recorded primary cause
of death, (b) gender, (c) ethnicity, (d) age at death, “t ” (e) year of
death, “y,” and allowed calculation of (f) year of birth, “h.” Age-
specific mortality from a defined disease effecting a specific gender
and ethnic group here characterized by the three related numbers,
year of birth (h), age at death (t ), and calendar year of death (y)
such that t = y− h. Biases such as misdiagnosis are recognized but
beyond the scope of this treatment.
Thus the data of annual number of deaths for lower GI tract
cancer mortality in European-American males from 1900 to 2006
may be represented as MOR (EAM, lower GI tract, y, t, h). Since
this paper will use only data for lower GI tract cancer in the EAM
group we will shorten this designation to the form MOR(y,t,h).
It is possible to group data entries into defined intervals of cal-
endar birth or death years or age of death as desired. Herein group
data from age of birth decades such that the grouped variable, h,
has values of 1800–1809, 1810–1819, . . ., 1990–1999, 2000–2006
(see text footnote 1). Similarly the calendar years of death may
be grouped such that the variable representing grouped calendar
years of death, y, has values of 1900–04, 1905–09, . . ., 1995–1999,
2000–2004, 2005–06. And the grouped variable for age of death, t,
has values of 1, 2, 3, 4, 5–9, 10–14, . . ., 95–99, 100–104.
For studies of age-specific cancer rates, the data are organized
as birth year cohorts and age of death intervals as, for instance,
MOR(h,t ) in which the grouped mortality data for each birth-
decade cohort, e.g., 1890–99 would be plotted as a function of age
of death intervals in adult life, t = 15–19, . . ., 100–104.
The raw data from which all other variables are derived are the
number of deaths reported each year, MOR(h,t ), and the reported
population size, POP(h,t ). Their ratios, OBS(h,t ) serve as a raw
estimate of age-specific (t ) death rates (deaths per person alive
within the age interval) for each defined birth cohort (h).
However, historically high death rates from other causes among
the youngest and oldest members of the population automati-
cally lead to significant underestimation of persons who would
have died of the disease observed because they died within the
interval of another cause. To overcome this bias we needed a cor-
rection factor for each age of death interval of each birth cohort.
To provide this we defined the set of values for deaths by all causes
(total deaths) in each age of death interval as TOT(h,t )=MOR[all
causes, (h,t )/POP(h,t )]. We reasoned that a first order correction
for coincident forms of death could be accomplished by defining
a coincidence corrected age-specific mortality rate, OBS∗(h,t ):
OBS(h, t ) = MOR(h, t )/POP(h, t ) (1)
TOT(h, t ) = MOR(all causes)(h, t )/POP(h, t ) (2)
OBS∗(h, t ) = OBS(h, t )/[1− TOT(h, t )+OBS(h, t )] (3)
In Table 1 we show the exact steps used to define OBS∗(h,t )
for the birth-decade cohort h= 1890–99 for the age of death
interval t = 100–104 years for lower GI tract cancer in European-
American males. Here it may be seen that the estimate of
OBS∗(h,t )= 501× 10−5 is derived as shown from 10 separate
estimates of the number of recorded deaths, MOR(h= 1890, . . .,
1899, t = 102) and corresponding 10 separate population values,
POP(h= 1890, . . ., 1899, t = 102) corrected for coincident deaths
within each year by the values of TOT(h= 1890, . . .,1899, t = 102).
Accounting for historical improvements in colorectal cancer
treatment
Given the values of OBS∗(h,t ) one must account for the fact
that a correctly diagnosed tumor of the lower GI tract would
not necessarily be mortal. There is convincing evidence that the
probability of surviving at least 5 years after competent diagnosis,
SUR(h,t ), has been rising over the last ∼70 years (14, 20). The
values of OBS∗(h,t ) derived from deaths alone must represent
an underestimate of the age-specific disease incidence, defined
here as the fraction of persons at a given age in which the dis-
ease first appears, INC(h,t ). If the values of SUR(h,t ) are available,
the estimate of disease incidence may be improved by calculating
INC(h,t )=OBS∗(h,t )/[1− SUR(h,t )].This step is illustrated in
Table 2 in which the values of OBS∗(h,t ) are transformed into val-
ues of INC(h,t ) by use of historical 5-year post-diagnosis survival
estimates for lower GI tract cancer (14).
INC(h, t ) = OBS∗(h, t )/[1− SUR(h, t )] (4)
Estimation of survival rates especially in old age continues to
be a source of considerable uncertainty. Here we used the values
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Table 1 | Arithmetic steps in definition of OBS∗(y =1992, . . ., 2001; t =100–04 years), from reported deaths, MOR(y,t ) for lower GI tract cancer











1992 1890 27 4656 0.44 580 1035
1993 1891 19 6281 0.35 303 466
1994 1892 19 6484 0.36 293 458
1995 1893 18 6847 0.36 263 411
1996 1894 24 7273 0.34 330 500
1997 1895 20 7642 0.36 262 409
1998 1896 25 7682 0.32 325 478
1999 1897 22 7719 0.32 285 419
2000 1898 23 7753 0.32 238 350
2001 1899 30 8272 0.29 363 511
1992–2001 1890–1899 501
This is the age-specific death rate corrected for coincident deaths in the same reporting years, y. Applies eqs 1, 2, and 3. Note that these data comprise the set used
to define the value of OBS*(h=1890–99, t=100–04) for the birth-decade cohort of 1890–99 dying from colorectal cancers in the 100–104 age interval, the mid year
age being 102 years: 1992–102⇒1890, 1993–102⇒1891, . . ., 2001–102⇒1899.
Table 2 | Arithmetic steps in definition of INC(h,t ), the age-specific incidence rate for cohort h corrected for historically improving 5-year survival
rates, SUR(h,t ), shown here for lower GI tract cancer for two birth-decade cohort intervals of birth, h=1890–99, and h=1900–09. Applies eq. 4.
Age at death
interval, t
OBS(h,t ) OBS*(h,t ) SUR(h,t ) INC(h,t ) OBS*(h,t ) SUR(h,t ) INC(h,t )
h=1890–9 h=1890–9 h=1890–9 h=1890–9 h=1900–9 h=1900–9 h=1900–9
15–19 5.49E−06 5.49E−06 0.1 6.10E−06 4.96E−06 0.15 5.84E−06
20–24 1.02E−05 1.07E−05 0.1 1.19E−05 9.64E−06 0.2 1.21E−05
25–29 1.58E−05 1.59E−05 0.15 1.87E−05 1.72E−05 0.25 2.29E−05
30–34 3.02E−05 3.00E−05 0.2 3.76E−05 3.15E−05 0.3 4.50E−05
35–39 5.12E−05 5.09E−05 0.25 6.78E−05 5.54E−05 0.33 8.27E−05
40–44 1.02E−04 1.03E−04 0.3 1.47E−04 8.88E−05 0.33 1.33E−04
45–49 1.81E−04 1.83E−04 0.33 2.74E−04 1.49E−04 0.4 2.48E−04
50–54 2.99E−04 3.12E−04 0.33 4.65E−04 2.57E−04 0.4 4.28E−04
55–59 4.74E−04 4.92E−04 0.4 8.20E−04 4.46E−04 0.44 7.96E−04
60–64 7.61E−04 7.87E−04 0.4 1.31E−03 7.48E−04 0.44 1.34E−03
65–69 1.16E−03 1.22E−03 0.44 2.18E−03 1.18E−03 0.44 2.11E−03
70–74 1.69E−03 1.80E−03 0.44 3.21E−03 1.76E−03 0.44 3.14E−03
75–79 2.30E−03 2.52E−03 0.44 4.49E−03 2.44E−03 0.44 4.36E−03
80–84 3.04E−03 3.44E−03 0.44 6.15E−03 3.27E−03 0.44 5.84E−03
85–89 3.82E−03 4.60E−03 0.33 6.86E−03 4.14E−03 0.44 7.39E−03
90–94 4.46E−03 5.91E−03 0.22 7.58E−03 4.72E−03 0.33 7.04E−03
95–99 4.24E−03 6.56E−03 0.11 7.37E−03 5.51E−03 0.22 7.06E−03
100–104 2.93E−03 4.91E−03 0 4.91E−03 3.85E−03 0.11 4.33E−03
recorded in various clinical studies for American males up to age
80–84 (14) and estimated subsequent values as a linear decline
to SUR(h,t )= 0 at age 100–104 based on discussions with clini-
cians about their experiences with declining use of surgery and/or
other attempts at therapy in the extremely aged. The estimates
of SUR(h,t ) used for the birth cohorts of 1890–99 and 1900–99
are listed in Table 2 so that readers may understand this process
and that our estimates of SUR(h,t ) for ages 85–104 are “best
guesses.”
Test cohort: EAM lower GI tract cancer mortality in the U.S.,
1900–2006
Deaths from cancer of the lower gastrointestinal tract (present
ICD9 codes: 152, 153, 154) are predominantly from colorectal
cancer (see text footnote 1). Figure 1A uses a semi-log plot to
illustrate the transformations from raw mortality rates to inci-
dence rates: from OBS(h= 1890–99, t ) to OBS∗(h= 1890–99, t ),
then to INC(h= 1890–99, t ). Also shown is the result of the same
transform of the data of the birth cohort of the succeeding decade,

























































Kini et al. Metakaryotic stem cell cancer model
INC(h= 1900–09, t ), which yielded similar estimates of for all
values of “t ” (Table 2).
In Figure 1B the coincidence adjusted mortality rate, OBS∗(h,t )
is presented as a function of age of death, t, on a semi-log scale
for each of successive birth cohort intervals, “h,” from 1800–09
through 2000–06. These data demonstrate that colorectal can-
cer death rates in older adults (t > 65) rose throughout the birth
cohorts of the nineteenth century reaching an approximately sta-
ble maximum in and after the birth cohort of 1880–89 modified to
the extent discussed above by improvements in medical treatment
represented by increasing values of SUR(h,y).
In Figure 1C these same data for colorectal cancer are plotted
so that changes OBS∗(h,y) as a function of age of death interval,
“t ” may be seen as functions of historical year of death interval “y.”
Here one may clearly see the historical changes in successive birth
cohorts as maximum mortality rates rose for unknown reasons in
cohorts born in the early nineteenth century and declined steadily
for cohorts living in the twentieth century when improved surgical
procedures increased survival rates.
In Figure 1D the data are plotted as OBS∗(y,t ) vs. “y” to illus-
trate the historical changes within each age of death interval, “t ”
as a function of historical year of death interval, “y.” This form of
presentation shows a significant decrease in older adult death rates
ascribable in whole or part to advances in medical practice after
1950 that increasingly effect each successive birth cohort (Table 2)
and a marked, previously unrecognized and unexplained decrease
in pediatric death rates dating from∼1940.
AMENDMENTS OF THE ARMITAGE–DOLL “TWO-STAGE” CANCER
MODEL
Limitation of initiation mutations to the fetal/juvenile stem cell
doublings
Growth of normal fetal/juvenile stem cells is here modeled as a
series of “a” net binomial doublings (a= 0, 1, 2, . . ., amax) defin-
ing the growth of the number of stem cells in an organ, N (a),
throughout fetal and juvenile growth to maturity. This does not
mean that we assume that each and every fetal/juvenile cell sur-
vives and grows exponentially by binomial fissions. We are aware
that many organs, e.g., lung, breast, prostate, vascular system, grow
as arborated ductal structures. But we note that their net growth
may be reasonably approximated as a binomial expansion. Our
mutation rates are in essence the probability that any new cell
in the stem cell expansion resulting in a mature organ has newly
acquired a required oncomutation (event) in the net cell doubling
interval represented by “a.”
The number of fetal stem cells during growth N (a) is thus sim-
ply represented as N (a)= 2a. Initiation is postulated to occur in
any stem cell by acquisition “n” required initiation mutations, i,
j, . . ., n, occurring in any order at constant mutation rates Ri, Rj,
. . ., Rn per doubling (14, 20). The expected number of newly ini-
tiated stem cells in each doubling period “a,” NEWinit(a) may be
expressed as:




a(n−1)2a 0 ≤ a ≤ amax (5)
In the fetal/juvenile model organogenic stem cells are posited to
reach maturity represented by“amax”doublings with high constant
mutation rates and to undergo metamorphosis to maintenance
stem cells with no net additional net cell growth and much lower
mutation rates (6).
Assuming each of the ∼107 adult colonic crypts to be rep-
resented at juvenile/adult metamorphosis by a single metakary-
otic stem cell, the number of net doublings at maturity, amax,
is about 23.25, i.e., 107 ∼223.25 (14, 20). The metakaryotic
mutator/hypermutable stem cell lineage of human organ anla-
gen is here formally postulated to begin in gestational week
4–5 with creation of two metakaryotic stem cells from sym-
metrical amitosis of a single precursor embryonic mitotic
stem cell at a= 0 (4). At birth, we estimate that a human
colon contains ∼220 colonic crypts each containing a basal
metakaryotic stem cell; thus at birth, a ∼20, at maturity,
a= amax∼ 23.25.
Promotion mutations during preneoplastic stem cell doublings
While the age of the developing organ may be designated as “a,”
each initiated stem cell arises as a single cell and is here posited to
double in parallel with its organogenic lineage till amax and then
continue to grow in adult tissue at a rate of doubling, µ, similar
to that of the juvenile organ in which it resided (14). At matu-
rity, initiated colonies arising early in fetal growth will be larger
than those initiated at the last pre-maturation doubling that would
consist of a single initiated stem cell. (30, 31) Each initiated colony
is posited to grow at a constant rate, µ, until one preneoplastic
stem cell experiences “m” required events to promote it to a neo-
plastic stem cell that founds a rapidly growing, potentially lethal
adenocarcinoma with sequelae, including metastasis, leading to
death. Here we adopt the suggestion of Armitage and Doll (1)
that the time between promotion and death is about 2.5 years in
adults.
Transforming stem cell doublings, g, into human age, t
In order to express the idea that initiated colonies arise through-
out fetal/juvenile growth of organogenic stem cells and con-
tinue to grow in adult tissues we needed to define a continu-
ous variable that expressed the age and, therefore the size, of
each preneoplastic lesion throughout both fetal/juvenile and adult
life.
To this end we introduce the continuous variable “g ” that is
equal to “a” for all values of “a” from a= 0 to a= amax and then
increases by one (1) for each adult preneoplastic stem cell doubling
period in years represented by 1/µ where µ is the doubling rate
of stem cells in an adult preneoplasia. Assuming an age of organ
maturity as∼16.5 for males and a 2.5-year interval between a pro-
motion event in an initiated preneoplastic stem cell and death, the
relationship between age in years, t, and age in terms of stem cell
doublings since the beginning of organogenesis when a= g = 0 is
simply:
g = µ (t − 16.5− 2.5)+ amax = µ (t − 19)+ amax (6)
This introduction of the parameter “g ” is essential to our mod-
eling approach in that it provides a means to relate events driven
by stem cell doubling intervals, “g,” to mortality rates recorded in
age of death intervals in adult life, “t.”

























































Kini et al. Metakaryotic stem cell cancer model
Assembling the elements into a single continuous model of cancer
incidence
After initiation in any fetal/juvenile doubling “a” growth of pre-
neoplastic stem cells as a colony is modeled as a series of “(g − a)”
binomial doublings [(g− a)= 0, 1, 2, . . .]. In each preneoplas-
tic stem cell doubling events such as mutations may occur until
any preneoplastic stem cell experiences “m” required promotion
events (A, B, . . .m). These events are posited to occur at constant
mutation rates per doubling: RA, RB, . . ., Rm. The expected num-
ber of newly initiated stem cells in preneoplastic doubling period









g − a)(m−1)2(g−a) 0 ≤ (g − a) (7)
Under these assumptions the number of organogenic dou-
blings “a” at initiation and the number of preneoplastic doublings
“(g− a)” after initiation sum to “g.” In each organogenic-doubling
interval “a” new preneoplastic colonies are created (initiated) and
these colonies grow until promotion and subsequent death remove
them.
For each organogenic stem cell doubling period “a” we now
require an expression for the expected number of colonies per
individual that are promoted in any interval of (g− a) thereafter.
Since the promotion of a preneoplastic stem leads to death the
number of surviving preneoplastic after initiation in interval “a”
will decline in each interval (g− a).
For the set of initiated colonies arising in organogenic interval
“a” the expected number of promotions in the subsequent lifetime
intervals, g, EXP(a→ g ) may be expressed as:
EXP
(

















g − a) (8)
While this expression may be computed for all values of “n”and
“m” and is used in our computations for varying values of “n” and
“m” below, we here introduce the restriction of n= 2 and m= 1
for the purpose of clearer illustration.














Of course, the expected number of promotions to neopla-
sia in an adult in any interval “g,” V (a→ g ), is simply the
sum of expected promotions to neoplasia from the initiations
of organogenic stem cells in each of the organogenic stem cell
doubling intervals of a= 0 to a= amax:
V (a→ g )
=
∑
(a = 0 to amax) 2 ln 2RiRj RA 2g a exp(−RA2(g−a))
(10)
This process is illustrated in Figure 2 in which the contribu-
tion to promotion at age “g ” from initiation at each organogenic
doubling “a” is shown to rise and fall with “(g− a).”
Figure 2 embodies our central argument that initiation is
restricted to the metakaryotic stem cell doublings of organogenesis
in the fetal/juvenile period.
The sum of these terms from initiations in all organogenic-
doubling intervals “a” approximates well the observed lifetime
incidence rate of many cancer types including colorectal cancer:
it increases sub-exponentially, reaches a maximum in old age and
declines appreciably in extreme old age. The earliest initiations of
fetal organogenesis drive the tumor incidence rate of juveniles and
young adults, the initiations of adolescent organogenesis drive the
tumor incidence rate in extreme old age (31).
Under these conditions the expected number of newly pro-
moted lesions through the end of any adult lifetime doubling
interval “g,” CAL(g ), is:
CAL(g ) = (1− e−V (a→g )) (11)
Additional possible modeling elements
Stratification of risks in the population. Stratification, or differ-
ences, within the population may encompass any environmental
or heritable condition required for cancer death. Some environ-
mental risks appear to operate through growth stimulation of
preneoplastic colonies as opposed to induction of initiating or pro-
moting oncomutations, e.g., persons exposed to sunlight as adults
or adult cigarette smokers. Populations may thus be “stratified”
on the basis of exposure to such preneoplastic growth-promoting
agents.
Other risks may well be stratified including fetal/juvenile initi-
ation mutation rates (6, 32), promotion mutation rates, growth of
promoted neoplastic stem cells (tumor progression), and tumor
invasion/metastasis. It is well to note that mortality data modeling
provides information about the subpopulation at risk for a form
of cancer but nothing about persons who are not at risk.
We have previously represented the fraction of the population
in whom all of the potential conditions necessary for cancer death
are present as “F” imagining that a person either is or is not at risk
for all necessary oncogenic processes. The corresponding fraction
in which one or more necessary condition(s) of risk is absent has
been represented as (1− F) (14, 20). Stratification need not, how-
ever, be an “all or none” phenomenon. Children grow to different
sizes, which may create stratification with regard to the maximum
number of stem cells at risk of initiation 2amax . Children also grow
at different rates and so may the preneoplastic lesions in different
persons. We have reported stratification with regard to mutation
rates in fetal/juvenile growth for both mitochondrial and nuclear
genes (9). In progress is an effort to incorporate stratification with
regard to initiation and promotion oncomutation rates and the
growth rates of preneoplasias. Here we continue to employ “F” as
an approximation for more precise stratification variables. Equa-
tion 11 rewritten to account for stratification in this way creates
the model:
CAL(g ) = F(1− e−V (a→g ))/[F + (1− F)e
∫
V (a→g )dg ] (12)
Competing forms of risk potentially affecting age-specific cancer
rates. Epidemiological observations have also demonstrated that
forms of cancer may share environmental or inherited risk factors

























































Kini et al. Metakaryotic stem cell cancer model
FIGURE 2 | Illustration of how initiation of organogenic stem cells in
each successive stem cell doubling during fetal/juvenile growth to
maturation contributes additively to the expectation of promotion (and
death) throughout life. Here the beginning of organogenesis is represented
as a=g =0, birth is at approximately, a=g =20, and maturity is at
a= amax =g =23.25. For a preneoplastic stem cell growth rate of µ=0.2 the
maximum value of V (a→g) is reached at g =37 or about or about
t =90 years and g =40 corresponds to t ∼105 years. Note that earliest
initiations presage fetal, juvenile, and young adult deaths. Initiations late in
organ development account for deaths in extreme old age. Note the expected
number of promotions (deaths), V (a→g) increases sub-exponentially from
g =23 to a maximum at g∼37 and then declines rapidly. In this example
g =40 represents ∼105 years of age. Values used in this illustration were
n=2, m=1, R i =R j =2.2×10−5, and RA =4.4×10−5.
with another, e.g., breast and ovarian cancers, in which the death
rates increase synchronously with age (see text footnote 1). The
term “f” has been previously introduced to represent the fraction
of persons that die of the observed cause among the set of mortal
diseases with shared risks and synchronous changes in death rates
(14, 20). We considered it possible that vascular disease death rates
that rise synchronously with cancer death rates might represent a
major form of competing risk. However, inspection of the stable
and then declining death rates from cerebrovascular and cardio-
vascular death rates 1900–2006 while colorectal cancer rates have
increased to stable maxima (accounting for increased survival)
indicates that risks for vascular disease and colorectal cancer are
probably not shared (see text footnote 1). Herein, treating colorec-
tal cancer specifically, we have assumed pro tempore that there are
no synchronously competing forms of death with shared risks for
colorectal cancer (34), i.e., f= 1.0. As noted, this assumption is not
valid for other forms of cancer such as breast, uterine, and ovarian
cancers, which appear to share risk factors.
A COMPUTER PROGRAM TO ESTIMATE PARAMETERS OF
CARCINOGENESIS IN THE TWO-STAGE MODEL ADJUSTED FOR
FETAL/JUVENILE INITIATION: CANCERFIT V5.0
Using CancerFit v5.0
In order to permit cancer clinicians and biologists to explore
quantitative hypotheses linking a wide range of biological and
population parameters to observed lifetime incidence rates the
computer program CancerFit v5.0 was developed and is avail-
able without cost from the corresponding author or by down-
load from http://mortalityanalysis.mit.edu. Any computer car-
rying MatLab©v.7.14 can run this program. Data for any form
of cancer downloaded from http://mortalityanalysis.mit.edu as
OBS∗(h,t ) and be directly imported into the program for the
desired country (U.S. or Japan), gender, ethnic group, and birth
year interval. Values of the parameters (ΠRi)1/n, (ΠRA)1/m,µ, and
F may be either fixed or permitted to range with a chosen number
of iterations for computation within each parameter range chosen
by the researcher. On a typical 2009 computer such as a MacIn-
tosh G5® 109 iterations of parameter combinations can be run in
about 4 h. In typical use the combinations of variable iterations
may range from 204 to 205 (1.6× 105 to 3.2× 106) requiring a few
minutes for computation. The results of a single computation run
are presented as the set of 100 best fits of the stipulated model to
the values of INC(h,t ) as defined below.
The researcher may then inspect the ranges of values of all five
parameters that together result in calculated age-specific incidence
estimate CAL(h,t ) in good agreement with observation, INC(h,t )
for the stipulated values of “n,” “m,” and “amax.” The tabulated
results also provide the estimated parametric values for the frac-
tion of persons initiated, F init, and the area computed under the
function CAL(h,t ), AREA(h), from g (or t )= 0 to ∼150 years,

























































Kini et al. Metakaryotic stem cell cancer model
which roughly estimates the expected (potential) number of lethal
events from the observed disease per person over the lifetime of the
cohort. Graphic representations are provided comparing CAL(h,t )
to INC(h,t ) for any desired fit in terms of linear or log values of
INC(h,t ) vs. linear or log values of age of death,“t.” It is hoped that
this program and the organized set of U.S. and Japanese mortality
data for a large set of cancer sites (see text footnote 1) will enable
cancer researchers and students to explore quantitative hypothe-
ses about cancer etiology from both a historical and age-specific
perspective for the genders and ethnic groups represented.
Ranges of parameter values employed in calculating values of
CAL(h,t) for colorectal cancer
The central premise of the fetal/juvenile mutator/hypermutable
stem cell hypothesis is that initiation mutations occur before adult-
hood when the maximum number of juvenile stem cells, 2amax is
reached, i.e., 0≤ a≤ amax (6, 35, 36). In CancerFit v5.0 the value of
amax must be specified for each organ studied, here we used 23.25
as an estimate for the colon/rectum (14). The values of F must lie
between 0.0 and 1.0; for computation of CAL(h,t ) 20 values, 0.05,
0.1, . . ., 0.95, 1.0, were used for each. Combinations of n= 1–5
and m= 1–5 were independently explored. Values of µ, the pre-
neoplastic annual net growth rate, ranged with 20 linear iterations
from 0.1 to 0.3 bracketing estimates from the annual growth rates
of juvenile body mass, ∼0.16 (14, 20). Values of (ΠRi)1/n repre-
senting the geometrical average of required oncomutation rates
in initiation and of (ΠRA)1/m representing the geometrical time-
averaged required onco-event rates in promotion ranged from
10−9 to 100 with 100 geometric iterations. After these geometrical
means were approximated, the values were bracketed more closely
to asymptotically obtain the best fits for each combination of n
and m tested.
Goodness of fit
The values of INC(h,t ) vary more than a thousand-fold among
the 18 age of death intervals recorded from maturity to old
age (Figure 1). Statistical comparison of CAL(h,t ) to INC(h,t )
required a term that gave equal weight to all 18 intervals. Such a
term is (log10 CAL(h,t )− log10 INC(h,t )( that is zero when the
terms are identical, i.e., their ratio is equal to 1.0. The square root
of the average of the square of these 18 terms is here employed as
a goodness of fit parameter, GOF(h,t ).
GOF (h, t ) =
{∑[





GOF(h,t ) is thus akin to a standard deviation of (log10
CAL(h,t )− log10 INC(h,t )( averaged over all adult life. If
GOF(h,t )= 0.1 then the 95% confidence limits of the average
ratio of CAL(h,t )/INC(h,t ) would be 10−0.2 and 100.2 or 0.63 and
1.58. If GOF(h,t )= 0.03 the 95% limits would be 0.93 and 1.07. A
GOF(h,t ) of greater than 0.1 suggests a poor fit of the model with
stipulated parameters “n” and “m” or marked errors in the val-
ues of INC(h,t ) arising from either sampling error or bias. Errors
arising from small sample sizes do not contribute significantly to
GOF(h,t ) when large U.S. European-American cohorts are stud-
ied. In the death intervals containing the fewest recorded deaths the
Table 3 | Matrix of goodness of fit calculated as GOF(h,t ) for n=1, 2, 3,
4, 5 and m=1, 2, 3, 4, 5 under the parsimonious conditions of
homogeneous risk (F =1) and no synchronous mortal diseases
sharing risk factors with colorectal cancer (f =1).
n
1 2 3 4 5
1 0.066 0.085 0.098 0.128 0.094
2 0.072 0.079 0.084 0.052 0.074
m 3 0.064 0.089 0.078 0.055 0.089
4 0.098 0.109 0.098 0.071 0.103
5 0.088 0.107 0.114 0.087 0.110





RA)1/m were permitted to range from 10−9 to 10 0 and the range
of µ was set at 0.1–0.3. The results illustrate the fact that values of n and/or m
cannot be derived by simply fitting the non-linear function, CAL(h,t) represented
by the algebraic model to the data, INC(h,t): multiple combinations of n and m
result in values of GOF(h,t) indicating reasonable correspondence of the model
to the data.
number of lower GI tract European-American male cancer deaths
recorded for the birth cohort of 1890–99 were 246 for t = 15–19
(1908–1917) and 1999 for t = 100–104 (1993–2002) respectively
(see text footnote 1). Based on the assumption of a Poisson distrib-
ution of deaths per living person within each age of death interval,
t, the GOF(h,t ) for two random samples of the same population
would yield an expected GOF(h,t ) of about 0.03.
Given the various biases and sampling errors expected for
measurements of OBS(h,t ), TOT(h,t ), and especially SUR(h,t )
defining the derived function INC(h,t ) this would be as good
a fit as might be expected for any model. When the values of
INC(h= 1890–99, t ) were compared to INC(h= 1880–89, t ) and
INC(h= 1900–09, t ) over all 18 age of death intervals GOF(t ) was
∼0.043 a number not much greater than the value∼0.03 expected
by chance alone (Table 3).
RESULTS
APPLICATION OF THE MODEL TO AGE-SPECIFIC COLORECTAL CANCER
INCIDENCE IN A SPECIFIC COHORT
First, the best fits of CAL(h= 1890–99, 15< t < 104) were calcu-
lated for the 25 combinations of n= 1–5 and m= 1–5 under the
parsimonious conditions of homogeneous risk and no synchro-
nous mortal diseases sharing risk factors with colorectal cancer
(F = 1, f= 1). Values of (ΠRi)1/n and (ΠRA)1/m were permitted
to range from 10−9 to 100 and the range of µ was set at 0.1–0.3.
The complete matrix of results is provided in Table 3. For n= 2
(an appropriate biological value only if the loss of both copies of
the APC gene were necessary and sufficient for initiation in most
colorectal cancers) and m= 1 as default assumptions the GOF(h,t )
was 0.085.
Second, we considered the possibility that stratification of risks
within the population such as varying oncomutation rates might
account for the observed discordance (F, 1, f= 1). To do this we
compared CAL(h,t ) to INC(h,t ) under the additional assumption
of inhomogeneous risk(s), i.e., the parameter “F” representing
a hypothetical fraction of the population at risk was allowed to

























































Kini et al. Metakaryotic stem cell cancer model
Table 4 | Complete matrix of GOF(h,t ) for m=1, 2, 3, 4, 5 and
n=1,2,3,4,5 with the assumption of inhomogeneous risk, i.e., the
parameter “F ” representing a hypothetical fraction of the population
at risk was allowed to range from 0 to 1 (F <1) and no synchronous
mortal diseases sharing risk factors with colorectal cancer (f =1).
n
1 2 3 4 5
1 0.038 0.043 0.039 0.041 0.046
2 0.036 0.048 0.042 0.046 0.054
m 3 0.043 0.042 0.046 0.042 0.043
4 0.047 0.047 0.035 0.040 0.044





RA)1/m were permitted to range from 10−9 to 100 and
the range of µ was set at 0.1–0.3. Comparison with the values of GOF(h,t) of
Table 3 illustrates that the assumption of population inhomogeneity results in
better agreement between model and incidence data. Such inhomogeneity has
been reported as an appreciable range of fetal juvenile mutation rates for the
human lung bronchial epithelium (6).
range from 0 to 1. The value of 0.043 was the minimum GOF(h,t )
observed for n= 2, m= 1 and the concordance in the age range
80–104 was appreciably improved. The complete matrix of these
results is provided as Table 4.
Thirdly, we considered the possibility of both population inho-
mogeneity and a competing synchronous mortal disease having
genetic and/or environmental risks shared with colorectal cancer
(F < 1, f< 1). This assumption did not, however, further reduce
the values of GOF(h,t ) consistent with the assumption that other
appreciable forms of mortality do not share risk factors with lower
G.I. tract cancers (34).
Figure 3 graphically depicts the degree of concordance of the
trial conditions: F = 1 (population homogeneity with regard to
risk) and F < 1 (population inhomogeneity) with adult lifetime
incidence data for lower G.I. tract cancer in European-American
males born 1890–99 INC(h,t ). It should be noted that for the
assumption F = 1 discordance between INC(h,t ) and CAL(h,t )
was greatest at t > 75 years where underestimation of colorectal
cancer as a cause of death by as much as 30% has been suspected
in extreme old age (14, 20, 21, 37, 38). Note that our tactic of
converting the raw mortality rate estimate OBS(h,t ) to the coinci-
dental death corrected estimate OBS∗(h,t ) would not account for
under-diagnosis post mortem. However, when CAL(h,t ) accounts
both for fetal/juvenile mutation limitation (6) and the possibility
of risk stratification in the population (F < 1) fits are considerably
improved (Figure 3).
USE OF OBSERVATIONS IN HUMANS TO ESTIMATE NUMBER OF
EVENTS REQUIRED FOR INITIATION (n) AND PROMOTION (m) IN
COLORECTAL CANCER
Comparison of the predictions of the amended Armitage–Doll
two-stage model represented as CAL(h,t ) to the observed lifetime
adult age-specific incidence of colorectal cancer in European-
American males born 1890–99 or 1900–09, INC(h,t ) achieved a
higher degree of concordance over the entire adult lifespan than
has previously been reported for any previous model of human
cancer. This result is consistent with the hypothesis that tumor ini-
tiation mutations are limited to the stem cells of the fetal/juvenile
period and that there is a significant degree of heterogeneity of
risk factors in the population (F < 1). We have reported consid-
erable variation in the population with regard to fetal/juvenile
mutation rates in the human lung (6). However, as noted by Peto,
no determination of the values of the number of initiating (n) or
promoting (m) events is possible by this approach alone as evi-
denced by the good fits for all 25 combinations of n and m tried
(Table 4) (33).
However, we could now apply several observations delimiting
some of the key parameters and discover what, if anything, may
be suggested here using the stipulations that F < 1, f= 1.
First, we applied our observation that juvenile colonic crypts
each contain a single metakaryotic stem cell (4) and that the num-
ber of crypts in an adult male colon is about 107 or 223.25 (14).
This value we associated with the maximum number of juvenile
colonic stem cells before maturation to adult colonic maintenance
stem cells with a form of eukaryotic behavior, i.e., we estimated
that amax= 23.25.
Second, we again noted that colonic fetal/juvenile mutation rate
estimates of ∼2–5× 10−5 gene-inactivation mutations per juve-
nile stem cell doubling have been derived from observation of
adenomatous polyps or mutations in the colon for the APC and
OAT genes (11, 12). Independent of the value of m stipulated, the
only value of n that resulted in such an initiation mutation rate
range is 2. For n= 2 the estimated rate was∼3.5× 10−5; for n= 1,
∼5.7× 10−8; for n= 3,∼3.6× 10−4.
The provision of the fetal/juvenile stem cell mutation rate thus
permitted the conclusion that n= 2 events. These could comprise
loss of both maternal and paternal APC alleles in the numerically
dominant colorectal cancer pathway (24).
Third, we previously noted the annual juvenile mass doubling
rate of U.S. males is about 0.158, significantly lower than esti-
mates of preneoplastic growth rates of 0.18–2.0 generated when it
is assumed that n= 2 and m= 1 (14).
Fourth, we estimated loss of heterozygosity fractions for many
different polymorphic markers in colon tumors are about 0.125 for
a single alleles (14). With preneoplastic doubling rates estimated
to be between 0.158 and 0.2 the number of years between male
maturity and the age at which mortality rate reaches a maximum
represents about 15 doublings. We here made a rough estimate
from these values: 0.125/15= 8× 10−3 gene deletion events per
doubling. This represented a lower bound on gene-inactivation or
loss rates in preneoplastic stem cells. If loss of either allele for an
autosomal gene were a promotional event the rate would be twice
this estimate or >1.6× 10−2.
As the values of m from 1 to 5 (holding n= 2) increased,
the geometric mean of the promotion event (mutation) rates
increased. For m= 1 the estimate was 2.2× 10−5 similar to the
estimated rate of promotion events; for m= 2, ∼1.9× 10−3; for
m= 3, 7× 10−3; for m= 4, 1.4× 10−2; for m= 5,∼2.1× 10−2.
As the values of m increased the estimated growth rate of
preneoplastic stem cells decreased. A decrease in estimated preneo-
plastic doubling rates with increasing values of m was expected.
For values of m> 1, the generating function for promotion would
rise as (g− a)(m − 1) as originally imagined by the earliest cancer
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FIGURE 3 | Comparisons of observation INC(h,t ) (black circles) to
CAL(h,t ) (red, blue crosses) for the two-stage cancer model amended
for limiting tumor initiation mutations to the fetal/juvenile stem cells
and n=2, m=1. A remarkably good fit is obtained for the assumptions that
the population is homogeneous for risk factors such as oncomutation rates
and/or preneoplastic growth rates (F =1) and there are no competing
synchronous forms of death (f =1) [red crosses, GOF(h,t )=0.085].
However, a significantly lower value, GOF(h,t )=0.043 is observed when
population risk stratification is assumed (F <1). Allowing for the possibility
of an unknown competing synchronous form of death (f <1) did not
decrease the values of GOF(h,t ) further. These findings are spurring further
amendment of the two-stage model to use stratified variables for initiation
and promotion mutation rates, preneoplastic growth rate and number of
stem cells at maturity.
modelers (15–17). This supralinear term would force a decrease in
the estimate of the exponential growth rate of preneoplastic stem
cells,µ, in order to fit the data of INC(h,t ).
We noted that for m= 3,µ= 0.167, and the geometrical mean
of the three promotion event rates, (ΠRA)1/m was ∼7× 10−3.
For m= 4, µ= 0.162, and (ΠRA)1/m= 1.4× 10−2. For m= 5,
µ= 0.156, and (ΠRA)1/m= 2.1× 10−2. Given the several uncer-
tainties in the estimate of preneoplastic gene losses and the range
observed among losses, it seemed that values of m= 4 or 5 would
best fit the data. These observations further suggest that the growth
rate of preneoplastic stem cells in males is indistinguishable from
the juvenile growth rate of males,∼0.158 (14).
DISCUSSION
FETAL/JUVENILE MUTATION
Early cancer models posited that a constant number of adult cells
were at continuous risk of acquisition of a required set of onco-
mutations that resulted in lethal tumors (15–17). Platt’s questions
about selective growth advantage of early oncomutants (18) stim-
ulated the creation of the two-stage model of Armitage and Doll
in which initiation was restricted to a constant number of adult
cells (1). An alternate theory, fetal/juvenile or, more narrowly, ges-
tational initiation was based on Luria’s demonstration that in
a bacterial culture growing from a small number of cells early
mutations give rise to large mutant colonies and late mutations to
small ones (10). This concept was clearly applicable to the stem
cells of a growing organ. By maturity a stem cell initiated early in
development would create a large preneoplastic colony, an initi-
ation in the last juvenile doubling would create a single initiated
stem cell. Early cancers would arise from early developmental initi-
ation, cancers of extreme old age would arise from the last juvenile
initiation events (30, 31, 39, 40). In the algebraic model provided
here each successive net doublings of stem cells of the fetal/juvenile
period provides initiated colonies. Deaths from colonies initiated
in any specific doubling interval would be distributed over sub-
sequent years of life until all persons with initiated colonies have
died (Figure 2).
The Armitage–Doll two-stage model, CAL(h,t ), of age-specific
cancer rates amended to incorporate a (a) defined maximum num-
ber of pre-maturation colonic epithelial stem cells and (b) limi-
tation of tumor initiating mutations to the fetal/juvenile period
accurately predicts the observed incidence function INC(h,t ) for
colorectal cancer in the cohort examined.
Biological data supporting limitation of mutations to the
fetal/juvenile period were scant but suggestive. Brash and Pon-
ten reported that increases particular point mutant TP53 colonies
in human skin were restricted to the juvenile years and that
subsequent solar exposure in adults increased mutant colony size
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but not number (35, 36). More recently, the distributions of five
nuclear and 17 mitochondrial point mutations in adult human
lung epithelium were found to match a simple Luria–Delbruck
expansion of mutant stem cells for ten stem cell doublings prior
to maturity. Both the nuclear and mitochondrial mutant fractions
assayed in human lung epithelium remained constant over the age
range of patients, 35–76 years (6).
Consistent with the fetal/juvenile limitation of tumor initiating
mutations are the findings that (a) sunlight does not induce new
nuclear mutations in adult skin (35, 36) and (b) cigarette smoke
does not induce new nuclear or mitochondrial mutations in adult
human lung epithelium (6, 9). There appear to be no data indi-
cating that mutant fractions increase in adult solid organs (41)
although increases with age in circulating leukocytes have been
reported, see (6) for review. This requires rethinking about human
carcinogenesis in which it is generally believed (and taught) that
environmental mutagens continuously initiate tumors by act-
ing on adult stem cells despite the absence of any supportive
data.
MUTATOR/HYPERMUTABLE METAKARYOTIC STEM CELLS OF
ORGANOGENESIS AND CARCINOGENESIS
The observed high fetal/juvenile mutation rates have been associ-
ated with amitotic, non-eukaryotic cells that arise in the fourth-
to fifth-week of gestation that appear to serve as the stem cells of
human organogenesis and carcinogenesis (2, 3, 6, 32). These large
“metakaryotic” mononuclear cells or syncytia with bell shaped
nuclei are found in all human fetal/juvenile organs, preneoplas-
tic lesions, and neoplasias. They increase by symmetric amitotic
fission and have been observed to produce all parenchymal, subse-
quently mitotic, cell forms by asymmetrical mitotic fissions in tis-
sues derived from all three primordial germ layers (4). Metakary-
otes also display bizarre modes of chromatin organization (5)
and of DNA segregation that occurs prior to, or concomitant
with, DNA replication in sister cells (4). Curiously, the replica-
tion process appears to involve DNA copying by the error-prone
DNA polymerase β insofar as about half of cancer-initiating APC
point mutation hotspots sampled are attributable to errors of DNA
polymerase β copying undamaged DNA in vitro (42).
NUMBER (n) AND RATES OF REQUIRED INITIATING MUTATIONS
Within the algebraic expression of CAL(h,t ) the term (ΠRi)1/n
represents the geometrical mean of “n” initiating mutations. Esti-
mates of this parameter derived from best fits of the model given
the assumption of population stratification for n= 2 and m= 1–
5 were 3.5, 2.3, 2.8, 2.8, and 4.3× 10−5 respectively (Figure 3)
agreeing well with estimates from clinical enumeration of APC−/−
mutant polyps and OAT gene-inactivating mutation rates of ∼2–
4× 10−5 per stem cell doubling during colon organogenesis (11,
12). For n= 1, m= 1, F < 1, the rate estimate of (ΠRi)1/n is about
5.3× 10−8, for n= 3, m= 1, F < 1 about 2.8× 10−4. Values of
the geometrical mean of initiation mutations assuming values of
n other than 2 are thus clearly discordant with APC and OAT
colonic mutation rate estimates. These facts, derived from clini-
cal genetic observations in both inherited and sporadic forms of
colorectal cancers are wholly consistent with the conclusion that
n= 2 and inconsistent with values of n 6= 2.
NUMBER (m) AND RATES OF REQUIRED PROMOTION MUTATIONS
It is not mathematically possible to estimate “m” (Tables 3, 4)
or the related geometrical mean of promotion mutation rates,
(ΠRA)1/m by simply fitting CAL(h,t ) to INC(h,t ).
For n= 2 and m= 1, and F ≤ 1, we note that the estimated val-
ues of a hypothetical promotion mutation, (ΠRA)1/m, range from
1 to 5× 10−5, approximating the estimated geometric mean rate
of 2–5× 10−5 calculated for gene initiating mutations in APC or
OAT genes in the fetal/juvenile stem cells (11, 12).
For n= 2 and m= 4 or 5 and F ≤ 1 the values of (ΠRA)1/m
bracket the estimated mean rate of losses of heterozygosity
(LOH) of polymorphic markers in human adenocarcinomas of
∼8× 10−3. This calculation depended on the assumption that
LOH in colonic adenocarcinomas arose from events in preneo-
plastic stem cells and not for events in post promotion neoplastic
stem cell divisions. This conundrum points to the need for mea-
surements of point and larger chromosomal mutations in human
colonic adenomas.
While many kinds of genetic or epigenetic events might be
required in preneoplastic metakaryotic stem cells, the data sug-
gest that oncogene activation mutations, limited to a small set
of amino acid substitutions in a proto-oncogene, is an unlikely
candidate. Such events are expected to occur at rates some
100 time lower than gene-inactivation rates via point mutations
(43) Gene deletion pathways as represented by loss of heterozy-
gosity of polymorphic markers could not result in oncogene
activation. To date no example of a required proto-oncogene
activation has been found for any major form of human can-
cer (6).
However, the possibility of a large number of independent
promotion pathways each with lower event rates than calculated
here cannot be excluded (problem of potential parallel promo-
tion pathways). In a formal sense we cannot even exclude m= 0
because no genetic or other rare required event has been identified
for promotion for any human tumor.
ESTIMATION OF PRENEOPLASTIC GROWTH RATE, µ
Using the best-fit stipulated values for n= 2, F < 1 and any value
of m= 1–5, the preneoplastic growth rate “µ” was estimated to
range from ∼0.192 to 0.156. This may be compared to the juve-
nile growth rate of mass in males, 0.158, and females, 0.163 (14)
but somewhat lower than Armitage and Doll’s original estimate
that death rates doubled about every 5 years, i.e., a doubling rate
of 0.2 (1). For the conditions n= 2, m= 4 or 5 our estimates
of µ in preneoplastic colonic adenomas brackets the estimate of
male juvenile growth rates. It would seem prudent to consider the
possibility that preneoplastic stem cell growth rates might even
more closely approximate the juvenile growth rates than previously
suggested (14).
ENVIRONMENTAL CANCER RISKS DURING THE FETAL/JUVENILE
PERIOD
Agreement between the origins of adult somatic mutations in
mutator/hypermutable fetal/juvenile human stem cells and age-
specific cancer rates offers an explanation of epidemiological
associations between fetal and early childhood exposure to known
mutagenic stimuli, particularly sunlight (35).
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Generational changes of age and organ-specific cancer rates in
immigrant populations toward those of the new country of resi-
dence may also be thought of in terms of fetal/juvenile initiation
mutations. Adult immigrants would have experienced tumor ini-
tiation in the country of origin while children conceived and/or
raised in the new country would experience mutagenic stimuli dif-
fering from those of their parents’ land. In both older and younger
immigrants the environment of the new country would define pro-
motional stresses that might act in adults by inducing promotional
oncomutations and/or by selecting through growth stimulation
conditionally initiated stem cells acquired in the fetal/juvenile
period (44).
Similarly, the marked decrease in death rates from lower G.I.
tract (Figures 1C,D) and other incurable cancers in children and
young adults post 1940 may reasonably be attributed to a decline
in fetal/juvenile initiation mutation rates that began circa 1940 and
continued through 2006 (see text footnote 1). We note in passing
that these changes began very soon after vitamin supplementa-
tion was begun in the U.S., but the constant exponential decreases
persisting for more than 60 years may suggest other hypotheses.
Save for sunlight exposure of juveniles, however, there is no
direct evidence that environmental mutagens cause oncomuta-
tions in humans (41). “Spontaneous” mutation caused by simple
DNA polymerase misincorporation errors or errors following
DNA damage by endogenous processes could account for all
fetal/juvenile mutations save for juvenile mutation by sunlight.
Environmental mutagens may have been or still may be indirectly
responsible for some of these oncomutations. For these reasons
we cannot distinguish between the hypotheses that metakaryotic
stem cells of organogenesis are constitutively mutator (high spon-
taneous mutation rate), hypermutable (markedly susceptible to
endogenous or exogenous mutagenic agents), or both.
THE ASSUMPTION OF POPULATION HOMOGENEITY
When it was posited that the population is in some way inhomoge-
neous with regard to risk, F < 1, the fit of the model, CAL(h,t ) to
the recorded INC(h,t ) was significantly improved (Figure 3). One
form of risk stratification is represented by the ∼tenfold range
in colonic adenomatous polyp numbers observed among indi-
viduals of FAP families (11) that suggest a range of fetal/juvenile
APC mutation rates. A similar variation of numbers of mutant
crypts displaying loss of the second allele of (OAT) has been
observed in adult colon (12). The remaining discrepancies between
the two-stage model adjusted for fetal/juvenile initiation and the
colorectal cancer incidence data may thus lie principally in the
assumption of a homogeneous oncomutation rate that assumes
a Poisson distribution of initiating events among persons in each
organogenic stem cell doubling period. This oversimplification is
compensated only in part by positing a value of F < 1 (Table 4,
Figure 3).
THE ASSUMPTION OF SYNCHRONOUS COMPETING FORMS OF DEATH
Assuming a competing synchronous form of death with shared
risk(s) with colorectal cancer does not further increase goodness
of fit under best-fit conditions (Figure 3; Table 3) in accord with
epidemiological studies of familial colorectal cancer (34). This
possibility must however be considered for cancers such as breast
and ovarian cancers in which synchronous age-specific death rates
display shared familial risk.
THE ASSUMPTION OF A SINGLE PATHWAY OF INITIATION AND
PROMOTION
We and others modeling carcinogenesis have so far treated a special
limited case in which there is a single or predominant pathway to a
lethal cancer. Thus, for instance in the case of colorectal cancer we
assume a single pathway of initiation involving mutations i and j
that appear to be independent losses of the maternal and paternal
alleles of the APC gene conjoined to a single pathway of promo-
tion mutations A, B, C, D,. . .. However, it is already known that a
minor pathway to colon cancer exists involving point mutations in
the beta-catenin gene (45) so our calculations for initiation rates
are in fact a weighted average of the APC, beta-catenin, and other
unknown minor pathways.
A general case would encompass multiple initiation pathways
linked to one or more promotional pathways are responsible for
cancers in organs such as the lungs, prostate, breast, and pancreas
for which single tumor suppressor genes have not been found.
SUMMARY
These quantitative analyses/ruminations point to an amended
qualitative model of human carcinogenesis at least for colorec-
tal carcinogenesis. It seems that as metakaryotic stem cells grow to
form the colon they experience a very high mutation rate and that
in each organogenic stem cell doubling newly initiated stem cells
are created. The newly initiated cells of each stem cell doubling
grow at the same rate as their sister uninitiated stem cells during
the fetal/juvenile period but after maturity grow at a constant rate
similar to the juvenile growth rate of about 0.16 per year. Any ini-
tiated stem cell may experience additional promotion mutations
sufficient to create a first neoplastic stem cell that gives rise to a
rapidly growing tumor (adenocarcinoma) that may kill in situ or
through metastases.
If for any organogenic stem cell all necessary initiation and pro-
motion mutations occur before maturity a pediatric tumor would
be expected. But after maturity only stem cell lineages initiated
before maturity are expected to grow and create the exponential
increase in cancer deaths with adult age. Eventually, the subpopula-
tion that has experienced colorectal stem cell initiation is depleted
in the surviving population in extreme old age and death rates
from this form of cancer in the surviving population decline.
When matched to fetal/juvenile APC mutation rates derived
from observation of polyp number in FAP patients the num-
ber of initiation mutations, n, is consistent with two and only
two initiation events. A value of m= 4 or 5 is suggested if it
is assumed that gene-inactivating events occurring at rates esti-
mate from LOH fractions in adenocarcinomas are required for
promotion. Population risk stratification for initiation mutation
rates is indicated by a wide distribution of mutant numbers in
adult colons and by the fact accounting in part for said stratifi-
cation within the amended two-stage model improves the con-
cordance with age-specific colorectal cancer rates. These findings
point to the importance of mutagenesis in fetal and juvenile
stem cells as primary determinants of adult age-specific can-
cer rates and suggest that they account for inter-generational
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shifts in cancer risks among organs in immigrant popula-
tions and the observed exponential decline of recent decades
in pediatric cancer mortality in solid organs such as the colon
(Figure 1D).
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